MINDMAZE THERAPEUTICS HOLDING, known as Relief Therapeutics Holding AG, is a commercial-stage biopharmaceutical company operating within the Health Care sector, specifically in the Pharmaceuticals industry. The company is recognized for its focus on identifying, developing, and commercializing drugs and therapies targeting rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders. With its headquarters situated in Geneva, Switzerland, Relief Therapeutics Holding AG has established itself as a global entity in the biopharmaceutical landscape.
The company’s stock is actively traded on the SIX Swiss Exchange, with its currency denominated in Swiss Francs (CHF). As of July 7, 2026, the closing price of the stock was recorded at 0.185 CHF. Over the past year, the stock has experienced significant volatility, with a 52-week high of 4.49 CHF on October 7, 2025, and a 52-week low of 0.182 CHF on July 7, 2026. This fluctuation reflects the dynamic nature of the biopharmaceutical sector and the challenges associated with drug development and commercialization.
Relief Therapeutics Holding AG’s market capitalization stands at 28,170,000 CHF, indicating its valuation within the market. The company’s price-to-earnings (P/E) ratio is currently at -0.39, which is not uncommon for companies in the biopharmaceutical industry, particularly those in the commercial-stage that may not yet be generating positive earnings.
The company’s strategic focus on rare diseases positions it uniquely within the pharmaceutical industry, addressing unmet medical needs and potentially offering significant therapeutic advancements. Relief Therapeutics Holding AG’s commitment to innovation and its global operational reach underscore its role as a key player in the development of novel treatments for rare conditions.
For more detailed information about Relief Therapeutics Holding AG’s activities, offerings, and strategic initiatives, stakeholders and interested parties are encouraged to visit their official website at www.relieftherapeutics.com . This platform provides comprehensive insights into the company’s ongoing projects, research endeavors, and future outlook within the biopharmaceutical domain.
